For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
All Authors
AK

HCP Connect Clinical Author

Dr. Aditi Kulkarni

Neurology

Credentials: MBBS, MD (General Medicine), DM (Neurology)

Specialty

Neurology

Clinical Updates

13

Experience

5 Years

Author Biography

About Dr. Aditi Kulkarni

Dr. Aditi Kulkarni is a neurologist with 5 years of clinical experience. She holds a DM in Neurology following an MD in General Medicine, with a focus on headache disorders, multiple sclerosis, and neuroimmunology. She is drawn to advances in disease-modifying therapies. Her writing makes evolving neurology evidence clear and usable.

Published Work

Recent Clinical Updates

13 articles

Neurology

Oveporexton: Increases Wakefulness (MWT) 25.4 min in Narcolepsy Type 1

Oveporexton narcolepsy type 1 phase 2: mean MWT increases to 25.4 min vs −1.2 min at week 8; ESS and cataplexy improved (NEJM) [1].

Jul 23, 2026|5 min read|Via PubMed

Neurology

FDA Approves Leucovorin for Cerebral Folate Transport Deficiency

Leucovorin approved for cerebral folate transport deficiency (FOLR1-CFTD); FDA cleared first treatment with weight-based dosing guidance for adults and pediatric patients.

Jul 23, 2026|5 min read|Via DailyMed

Neurology

FDA Approves Glatiramer Acetate for Relapsing MS: HR 0.55 in Study 3

Glatiramer acetate relapsing multiple sclerosis: FDA approval and Study 3 result (HR 0.55).

Jul 17, 2026|6 min read|Via DailyMed

Neurology

efgartigimod: 68% MG‑ADL Response in ADAPT; SubQ VYVGART HYTRULO Dosing

efgartigimod myasthenia gravis: ADAPT showed 68% MG‑ADL response in AChR‑positive patients; VYVGART HYTRULO offers subcutaneous dosing per label.

Jul 12, 2026|6 min read|Via PubMed

Neurology

FDA Approves Subcutaneous Lecanemab: CDR‑SB −0.45 in CLARITY AD

lecanemab Alzheimer disease treatment: FDA added subcutaneous 360 mg weekly maintenance (IQLIK) after 18 months; CLARITY AD showed CDR‑SB −0.45 vs placebo.

Jul 11, 2026|6 min read|Via PubMed

Neurology

FDA Approves donanemab for Alzheimer: iADRS Benefit 2.92 Points

Donanemab (KISUNLA) FDA approval for Alzheimer disease: iADRS 2.92-point benefit, dosing, ARIA risks, and imaging‑guided therapy.

Jul 10, 2026|6 min read|Via PubMed

Medical Research

Type 2 Diabetes Linked to Faster Chronic Disease Onset

New research reveals type 2 diabetes accelerates development of multiple chronic diseases, particularly in middle-aged adults, impacting patient outcomes and treatment plans.

Apr 23, 2026|4 min read|Via Medical Xpress

Medical Research

Emotional Eaters Less Likely to Lose Weight on GLP-1 Therapy

Research reveals individuals who overeat for emotional reasons may have reduced weight loss success with GLP-1 receptor agonists like Ozempic.

Apr 19, 2026|4 min read|Via Medical Xpress

Healthcare Business

Reduce Mental Fatigue in Hearing Loss Patients by 30%

Discover how addressing hearing loss can improve mental health outcomes, reducing social isolation, anxiety, and depression in patients.

Apr 18, 2026|7 min read|Via American Journal Managed Care

Neurology

Boost Neurology Dept Efficiency with Effective Vice Chair Roles

Discover how evolving vice chair responsibilities can enhance neurology department leadership, faculty engagement, and alignment with institutional goals.

Apr 4, 2026|2 min read|Via Neurology Live

Health Information

Accurate RA Diagnosis in Less Time

Learn how lab tests and imaging help doctors diagnose rheumatoid arthritis quickly and accurately, reducing diagnostic time and improving patient outcomes.

Apr 2, 2026|6 min read|Via MedlinePlus

Medical Devices

Boost Breast Cancer Survival Rates with Latest Treatments

Discover how advances in breast cancer treatment are improving patient outcomes and survival rates, offering new hope for individuals diagnosed with the disease.

Mar 30, 2026|6 min read|Via Medical Device News Magazine

Medical Research

FDA May Drop Expert Reviews, Impacting Drug Approval

Proposed FDA policy change could reduce public scrutiny of new drug approvals, what it means for physicians and patient care decisions.

Mar 24, 2026|7 min read|Via Medical Xpress